Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models.

Poliaková M, Felser A, Pierzchala K, Nuoffer JM, Aebersold DM, Zimmer Y, Zamboni N, Medová M.

FEBS J. 2019 Apr 16. doi: 10.1111/febs.14852. [Epub ahead of print]

PMID:
30993872
2.

Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.

Orlando E, Aebersold DM, Medová M, Zimmer Y.

Cancer Lett. 2019 Feb 28;443:189-202. doi: 10.1016/j.canlet.2018.12.001. Epub 2018 Dec 11.

PMID:
30550851
3.

Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.

Nisa L, Barras D, Medová M, Aebersold DM, Medo M, Poliaková M, Koch J, Bojaxhiu B, Eliçin O, Dettmer MS, Angelino P, Giger R, Borner U, Caversaccio MD, Carey TE, Ho L, McKee TA, Delorenzi M, Zimmer Y.

Mol Cancer Res. 2018 Dec;16(12):1912-1926. doi: 10.1158/1541-7786.MCR-18-0056. Epub 2018 Aug 14.

PMID:
30108165
4.

Portable Health Care Facilities in Disaster and Rescue Zones: Characteristics and Future Suggestions.

Bitterman N, Zimmer Y.

Prehosp Disaster Med. 2018 Aug;33(4):411-417. doi: 10.1017/S1049023X18000560. Epub 2018 Jul 13.

PMID:
30001767
5.

Thermal imaging as a tool for evaluating tumor treatment efficacy.

Hoffer OA, Ben-David MA, Katz E, Zoltnik Kirshenabum D, Alezra D, Zimmer Y, Kelson I, Gannot I.

J Biomed Opt. 2018 May;23(5):1-6. doi: 10.1117/1.JBO.23.5.058001.

6.

Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Glück AA, Orlando E, Leiser D, Poliaková M, Nisa L, Quintin A, Gavini J, Stroka DM, Berezowska S, Bubendorf L, Blaukat A, Aebersold DM, Medová M, Zimmer Y.

Oncogene. 2018 Jul;37(30):4181-4196. doi: 10.1038/s41388-018-0256-6. Epub 2018 May 2.

PMID:
29717265
7.

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.

Poliaková M, Aebersold DM, Zimmer Y, Medová M.

Mol Cancer. 2018 Feb 19;17(1):27. doi: 10.1186/s12943-018-0798-9. Review.

8.

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.

Nisa L, Häfliger P, Poliaková M, Giger R, Francica P, Aebersold DM, Charles RP, Zimmer Y, Medová M.

Mol Cancer. 2017 May 22;16(1):93. doi: 10.1186/s12943-017-0660-5.

9.

Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cells.

Nita I, Hostettler K, Tamo L, Medová M, Bombaci G, Zhong J, Allam R, Zimmer Y, Roth M, Geiser T, Gazdhar A.

Sci Rep. 2017 Feb 3;7:41901. doi: 10.1038/srep41901.

10.

Software toolbox for analysis of the endometrial myometrial junction - a pilot study.

Aviram R, Aviram A, Gvili SO, Zimmer Y, Shulman A, Tepper R.

Clin Exp Obstet Gynecol. 2017;44(3):440-443.

PMID:
29949289
11.

Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.

Francica P, Nisa L, Aebersold DM, Langer R, Bladt F, Blaukat A, Stroka D, Martínez MR, Zimmer Y, Medová M.

Clin Cancer Res. 2016 Nov 1;22(21):5322-5336. Epub 2016 May 16.

12.

Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer.

Piguet AC, Medová M, Keogh A, Glück AA, Aebersold DM, Dufour JF, Zimmer Y.

Genes Cancer. 2015 Jul;6(7-8):317-327.

13.

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.

Mikami K, Medová M, Nisa L, Francica P, Glück AA, Tschan MP, Blaukat A, Bladt F, Aebersold DM, Zimmer Y.

Mol Cancer Res. 2015 Dec;13(12):1544-53. doi: 10.1158/1541-7786.MCR-15-0022. Epub 2015 Sep 10.

14.

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

Leiser D, Medová M, Mikami K, Nisa L, Stroka D, Blaukat A, Bladt F, Aebersold DM, Zimmer Y.

Mol Oncol. 2015 Aug;9(7):1434-46. doi: 10.1016/j.molonc.2015.04.001. Epub 2015 Apr 14.

15.

Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches.

Nisa L, Aebersold DM, Giger R, Caversaccio MD, Borner U, Medová M, Zimmer Y.

Cancers (Basel). 2015 Mar 31;7(2):585-97. doi: 10.3390/cancers7020585. Review.

16.

Interplay between receptor tyrosine kinases and hypoxia signaling in cancer.

Glück AA, Aebersold DM, Zimmer Y, Medová M.

Int J Biochem Cell Biol. 2015 May;62:101-14. doi: 10.1016/j.biocel.2015.02.018. Epub 2015 Mar 6. Review.

PMID:
25747905
17.

Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer.

Nisa L, Aebersold DM, Giger R, Zimmer Y, Medová M.

Pharmacol Ther. 2014 Sep;143(3):337-49. doi: 10.1016/j.pharmthera.2014.04.005. Epub 2014 Apr 27. Review.

PMID:
24786972
18.

Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.

Leiser D, Pochon B, Blank-Liss W, Francica P, Glück AA, Aebersold DM, Zimmer Y, Medová M.

FEBS Lett. 2014 Mar 3;588(5):653-8. doi: 10.1016/j.febslet.2013.12.025. Epub 2014 Jan 17.

19.

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects.

Medová M, Aebersold DM, Zimmer Y.

Cancers (Basel). 2013 Dec 19;6(1):1-27. doi: 10.3390/cancers6010001.

20.

The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.

Medová M, Pochon B, Streit B, Blank-Liss W, Francica P, Stroka D, Keogh A, Aebersold DM, Blaukat A, Bladt F, Zimmer Y.

Mol Cancer Ther. 2013 Nov;12(11):2415-24. doi: 10.1158/1535-7163.MCT-13-0151. Epub 2013 Sep 23.

21.

Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.

Humbert M, Medová M, Aebersold DM, Blaukat A, Bladt F, Fey MF, Zimmer Y, Tschan MP.

Biochem Biophys Res Commun. 2013 Feb 8;431(2):264-9. doi: 10.1016/j.bbrc.2012.12.120. Epub 2013 Jan 9.

PMID:
23313490
22.

MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest.

Medová M, Aebersold DM, Blank-Liss W, Streit B, Medo M, Aebi S, Zimmer Y.

Genes Cancer. 2010 Oct;1(10):1053-62. doi: 10.1177/1947601910388030.

23.

MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks.

Medová M, Aebersold DM, Zimmer Y.

Int J Cancer. 2012 Feb 1;130(3):728-34. doi: 10.1002/ijc.26058. Epub 2011 May 9.

24.

Incidence of small lymph node metastases with evidence of extracapsular extension: clinical implications in patients with head and neck squamous cell carcinoma.

Ghadjar P, Simcock M, Schreiber-Facklam H, Zimmer Y, Gräter R, Evers C, Arnold A, Wilkens L, Aebersold DM.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1366-72. doi: 10.1016/j.ijrobp.2009.09.043. Epub 2010 Mar 16.

PMID:
20231070
25.

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.

Zimmer Y, Vaseva AV, Medová M, Streit B, Blank-Liss W, Greiner RH, Schiering N, Aebersold DM.

Cancer Lett. 2010 Mar 28;289(2):228-36. doi: 10.1016/j.canlet.2009.08.017. Epub 2009 Sep 23.

PMID:
19783361
26.

Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3beta.

Banz VM, Medová M, Keogh A, Furer C, Zimmer Y, Candinas D, Stroka D.

Biochim Biophys Acta. 2009 Oct;1793(10):1597-603. doi: 10.1016/j.bbamcr.2009.08.002. Epub 2009 Aug 12.

27.

Quantitative analysis of extracapsular extension of metastatic lymph nodes and its significance in radiotherapy planning in head and neck squamous cell carcinoma.

Ghadjar P, Schreiber-Facklam H, Gräter R, Evers C, Simcock M, Geretschläger A, Blumstein NM, Zbären P, Zimmer Y, Wilkens L, Aebersold DM.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1127-32. doi: 10.1016/j.ijrobp.2009.03.065. Epub 2009 Aug 3.

PMID:
19647955
28.

MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers.

Ghadjar P, Blank-Liss W, Simcock M, Hegyi I, Beer KT, Moch H, Aebersold DM, Zimmer Y.

Clin Exp Metastasis. 2009;26(7):809-15. doi: 10.1007/s10585-009-9280-9. Epub 2009 Jul 29.

29.

Coupling of mutated Met variants to DNA repair via Abl and Rad51.

Ganapathipillai SS, Medová M, Aebersold DM, Manley PW, Berthou S, Streit B, Blank-Liss W, Greiner RH, Rothen-Rutishauser B, Zimmer Y.

Cancer Res. 2008 Jul 15;68(14):5769-77. doi: 10.1158/0008-5472.CAN-08-1269.

30.

Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.

Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME.

J Clin Oncol. 2008 Jun 20;26(18):3015-24. doi: 10.1200/JCO.2007.15.7164.

PMID:
18565887
31.

Understanding recent increases in the incidence of sexually transmitted infections in men having sex with men: changes in risk behavior from risk avoidance to risk reduction.

Marcus U, Bremer V, Hamouda O, Kramer MH, Freiwald M, Jessen H, Rausch M, Reinhardt B, Rothaar A, Schmidt W, Zimmer Y; MSM-STD-Sentinel Network.

Sex Transm Dis. 2006 Jan;33(1):11-7.

PMID:
16385216
32.

Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy.

Gruber G, Hess J, Stiefel C, Aebersold DM, Zimmer Y, Greiner RH, Studer U, Altermatt HJ, Hlushchuk R, Djonov V.

Br J Cancer. 2005 Jan 17;92(1):41-6.

33.

Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO).

Allal AS, Ares C, Dulguerov P, Tschanz E, Verdan C, Mhawech P, Riesterer O, Honer M, Vuong V, Jochum W, Zingg D, Bodis S, Ametamey S, Pruschy M, Inteeworn N, Ohlerth S, Höpfl G, Roos M, Wergin M, Rohrer Bley C, Gassmann M, Kaser-Hotz B, Berthou S, Aebersold DM, Ganapathipillai S, Streit B, Stalder D, Gruber G, Greiner RH, Zimmer Y, Lutters G, Krek W, Tenzer A, Hofstetter B, Bonny C, Azria A, Larbouret C, Cunat S, Ozsahin M, Zouhair A, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pèlegrin A, Heuberger J, Kestenholz P, Taverna Ch, Lardinois D, Jörger M, Schneiter D, Jerman M, Weder W, Stahel R, Bodis S, Vees H, Mach N, Hügli A, Balmer Majno S, Beer KT, Friedrich EE, Ciernik IF, Stanek N, Taverna C, Greiner R, Mahler F, Landmann Ch, Studer G, Bernier J, Gallino A, Juelke PD, Hafner HP, Jamshidi P, Erne P, Resink TJ, Thum P, Notter M, Bargetzi M, Suleiman M, Luthi JC, Bieri S, Curschmann J, Pajic B, Kranzbühler H, Lippold B, Ueltschi G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Gol-Ouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A, Jeanneret Sozzi W, Kramar A, Mirimanoff RO, Azria D, Taussky D, Becker M, Kranzbuehler H, Weitzel M, Bortoluzzi L, Behrensmeier F, Isaak B, Pasche P, Luthi F, Weber DC, Lomax AJ, Rutz HP, Pedroni ES, Verwey J, Goitein G, Timmermann B, Lomax A, Bolsi A, Weber D, Bentzen SM, Khalil AA, Saunders MI, Horiot JC, Van den Bogaert W, Cummings BJ, Dische S, Slosman DO, Kebdani T, Allaoua M, Stadelmann O, Stupp R, Pica A, Dubois JB, Oehler C, Ulmer U, Lütolf UM, Huser M, Burger C, Szekely G, Davis JB, Gervaz P, Gertsch P, Morel P, Roth AD, Zenklusen H, Schott A, Curti G, Schefer H, Kolotas C, Thalmann G, Vetterli D, Kemmerling L, Mini R, Rouzaud M, Nouet P, Mollà M, Escudé L, Miralbell R, Beer K, von Briel C, Jichlinski P, Guillou L, Fogliata A, Nicolini G, Cozzi L, Hafner HP, Hueber P, Szczerba D, Born EJ, Dipasquale G, Jargy C, Munier F, Balmer A, Do HP, Pasche G, Wang H, Moeckli R, Boehringer T, Coray A, Lin S, Pedroni E, Rutz H, Baumert BG, Norton IA, Schoenmaker E, Krayenbühl J, Bründler MA, Allemann K, Laluhovà D, Collen T, Coucke P, Ries G, Rufibach K, Huguenin P, Abdou M, Girardet C, Vees HJ, Bigler R, Özsoy O, Bouville S, Corminboeuf F, Betz M, Matzinger O, Tebeu P, Popowski Y, Verkooijen H, Bouchardy C, Ludicke F, Usel M, Major A, Merçay A, Pache G, Bulling S, Bressan S, Valley JF, Motta M, Presilla S, Richetti A, Franzetti A, Pesce G.

Strahlenther Onkol. 2004 Jun;180 Suppl 1:89-108. doi: 10.1007/BF03356735. No abstract available.

PMID:
27137923
34.

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.

Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y.

Oncogene. 2004 Jul 8;23(31):5387-93.

PMID:
15064724
35.

An automatic approach for morphological analysis and malignancy evaluation of ovarian masses using B-scans.

Zimmer Y, Tepper R, Akselrod S.

Ultrasound Med Biol. 2003 Nov;29(11):1561-70.

PMID:
14654152
36.

Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx.

Aebersold DM, Landt O, Berthou S, Gruber G, Beer KT, Greiner RH, Zimmer Y.

Oncogene. 2003 Nov 20;22(52):8519-23.

PMID:
14627992
37.

Image segmentation in obstetrics and gynecology.

Zimmer Y, Akselrod S.

Ultrasound Med Biol. 2000 May;26 Suppl 1:S39-40. No abstract available.

PMID:
10794871
38.

Genes induced by growth arrest in a pancreatic beta cell line: identification by analysis of cDNA arrays.

Zimmer Y, Milo-Landesman D, Svetlanov A, Efrat S.

FEBS Lett. 1999 Aug 20;457(1):65-70.

39.

Computerized quantification of structures within ovarian cysts using ultrasound images.

Zimmer Y, Tepper R, Akselrod S.

Ultrasound Med Biol. 1999 Feb;25(2):189-200.

PMID:
10320308
40.

Structure-function analysis of the trypanosomatid spliced leader RNA.

Goncharov I, Xu YX, Zimmer Y, Sherman K, Michaeli S.

Nucleic Acids Res. 1998 May 1;26(9):2200-7.

41.

Decay constant of Doppler flow waveform as a possible indicator of ovarian malignancy.

Tepper R, Keselbrener L, Manor M, Eyal S, Beyth Y, Zimmer Y, Akselrod S.

Ultrasound Med Biol. 1997;23(8):1171-7.

PMID:
9372565
43.
44.

A two-dimensional extension of minimum cross entropy thresholding for the segmentation of ultrasound images.

Zimmer Y, Tepper R, Akselrod S.

Ultrasound Med Biol. 1996;22(9):1183-90.

PMID:
9123643
45.

The distribution of the local entropy in ultrasound images.

Zimmer Y, Akselrod S, Tepper R.

Ultrasound Med Biol. 1996;22(4):431-9.

PMID:
8795170
46.

Ligand binding by fibroblast growth factor receptors investigated using chimeric receptor molecules.

Yayon A, Gray TE, Zimmer Y, Eisenstein M, Givol D.

J Recept Signal Transduct Res. 1995 Jan-Mar;15(1-4):185-97.

PMID:
8903940
47.

Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2).

Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D, Lonai P.

Dev Biol. 1993 Aug;158(2):475-86.

PMID:
8393815
49.
50.

Flg-2, a new member of the family of fibroblast growth factor receptors.

Avivi A, Zimmer Y, Yayon A, Yarden Y, Givol D.

Oncogene. 1991 Jun;6(6):1089-92. Erratum in: Oncogene 1992 Apr;7(4):823.

PMID:
1648703

Supplemental Content

Loading ...
Support Center